13020-34-3

Upstream product

• 29030-52-2 1-(4'-Cyclohexyl-phenyl)-1-hydroxy-ethane 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 931-50-0 cyclohexylmagnesium bromide 
• 75-07-0 acetaldehyde 
• 60-29-7 diethyl ether 
• 25109-28-8 4-bromo(cyclohexyl)benzene 

Downstream Products

• 20029-52-1 4-cyclohexylbenzoic acid 
• 476334-82-4 (1S,2S,6R,8S)-4-[(S)-1-Chloro-3-(4-cyclohexyl-phenyl)-propyl]-2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0^2,6]decane 
• 476334-81-3 (1S,2S,6R,8S)-4-[2-(4-Cyclohexyl-phenyl)-ethyl]-2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0^2,6]decane 
• 6908-41-4 4-(methoxycarbonyl)benzyl alcohol 

Relevant academic research and scientific papers

NOVEL METHOD FOR PREPARING STYRENIC OLEFINS

The present invention relates to a method for preparing a styrenic olefin. The method of the present invention comprises the steps of: adding a catalyst and a solvent in a reactor and heating the reactor to create a reflux state; adding an alcohol starting material to the reactor dropwise at a constant rate; removing water generated by adding the alcohol starting material from the reactor; and purifying the obtained styrenic olefin. The method of the present invention is advantageous in minimizing byproducts and preparing styrenic olefins having a variety of substituents in high yield.

Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3

A class of 3,5-diphenyl-1,2,4-oxadiazole based compounds have been identified as potent sphingosine-1-phosphate-1 (S1P1) receptor agonists with minimal affinity for the S1P2 and S1P3 receptor subtypes. Analogue 26 (S1P1 IC50 = 0.6 nM) has an excellent pharmacokinetics profile in the rat and dog and is efficacious in a rat skin transplant model, indicating that S1P3 receptor agonism is not a component of immunosuppressive efficacy.